SRX Global Inc SRXH
News
SRX Global Provides Update on Balance Sheet and Share Buyback
SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics’ Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies
SRX Global Commits $2.5 Million to Launch Multi-Strategy Trading Platform in Partnership with 5T Trading, Powered by the EMJX Platform
SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies
SRX Global Commits $1.5 Million to Launch Family of AI-Powered ETFs through its EMJX Platform, Partnering with Kupa AI Co-Founder Andy Kim
SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)
SRX Global CEO Kent Cunningham and President of EMJX Platform Eric Jackson to Present at Webull Corporate Connect Series Fintech Investment Webinar
SRX Global Provides Shareholder Update on Portfolio Company, ARMR Sciences, a Clinical-Stage Biodefense Company
SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers
